ライフサイエンスコーパス: congenital heart disease

1 plement a program dedicated to children with congenital heart disease.

2 affecting the interaction may contribute to congenital heart disease.

3 bodies and that their perturbation leads to congenital heart disease.

4 ifferences between patients with and without congenital heart disease.

5 n was detected in an individual with SIT and congenital heart disease.

6 ion in the transcription factor GATA4 causes congenital heart disease.

7 sight to the complex genetic architecture of congenital heart disease.

8 ms underlying normal cardiac development and congenital heart disease.

9 a devastating complication in patients with congenital heart disease.

10 teins in the pathology of L-R patterning and congenital heart disease.

11 in female patients with PAH associated with congenital heart disease.

12 jor contributor to mortality for adults with congenital heart disease.

13 sting as a cell source for heart failure and congenital heart disease.

14 morbidity and mortality among patients with congenital heart disease.

15 proportion of inpatient care costs in adult congenital heart disease.

16 monary arterial hypertension associated with congenital heart disease.

17 and in all patients with PAH associated with congenital heart disease.

18 ntal follow-up for all children with complex congenital heart disease.

19 lopmental disorders such as cleft palate and congenital heart disease.

20 lopment, and thus potential underpinnings of congenital heart disease.

21 V) dysfunction in patients after surgery for congenital heart disease.

22 erse event after cardiac catheterization for congenital heart disease.

23 e that includes developmental delay, but not congenital heart disease.

24 s with ischemic, valvular, hypertensive, and congenital heart disease.

25 can occur in both syndromic and nonsyndromic congenital heart disease.

26 by surgical repair in childhood versus adult congenital heart disease.

27 ond heart field is a predisposing factor for congenital heart disease.

28 mother can meaningfully reduce their risk of congenital heart disease.

29 ic dysfunction, or both, or various forms of congenital heart disease.

30 risk, and predictors in patients with adult congenital heart disease.

31 and defects in AVC maturation can result in congenital heart disease.

32 monary arterial hypertension associated with congenital heart disease.

33 developmental trajectories in children with congenital heart disease.

34 suggest a novel type of gain-of-function in congenital heart disease.

35 biological valve prosthesis in patients with congenital heart disease.

36 of late morbidity and mortality in repaired congenital heart disease.

37 tment of re-entry VT in adults with repaired congenital heart disease.

38 Its deregulation leads to congenital heart disease.

39 e variants, hypertrophic cardiomyopathy, and congenital heart disease.

40 ement as they affect outcome for babies with congenital heart disease.

41 lar cells to treat myocardial infarction and congenital heart disease.

42 uld be considered as a new causative gene of congenital heart disease.

43 tion, and outcomes of surgical patients with congenital heart disease.

44 the diagnosis and treatment of acquired and congenital heart disease.

45 the hypothesis that HIC2 hemizygosity causes congenital heart disease.

46 tant modifiable risk factor in neonates with congenital heart disease.

47 ndocardial) pacing approach in patients with congenital heart disease.

48 ment and the pathology associated with human congenital heart disease.

49 rnative to epicardial leads in patients with congenital heart disease.

50 y genes, which when mutated in human lead to congenital heart disease.

51 premature infants and children with complex congenital heart disease.

52 r heart disease, pulmonary hypertension, and congenital heart disease.

53 ng, and particularly on PHVD associated with congenital heart disease.

54 red in the growing and aging population with congenital heart disease.

55 urrently performed to treat single-ventricle congenital heart disease.

56 raniofacial gestalt, skeletal anomalies, and congenital heart disease.

57 ome (HLHS) is among the most severe forms of congenital heart disease.

58 Familial Ebstein anomaly is a rare form of congenital heart disease.

59 n for the management of vascular stenosis in congenital heart disease.

60 a exist on the long-term prognosis of simple congenital heart disease.

61 r research with translational implication in congenital heart diseases.

62 ay also help to gain molecular insights into congenital heart diseases.

63 ed studies about the application of DSCT for congenital heart diseases.

64 hat are associated with cardiomyopathies and congenital heart diseases.

65 ascular access, high infection risk, or some congenital heart diseases.

66 Among patients with adult congenital heart disease, 1 in 11 men and 1 in 15 women

67 Of 28 children undergoing surgery for congenital heart disease, 15 underwent tight glycemic co

68 ion and intervention for pediatric and adult congenital heart disease (20,169 procedures in 76 hospit

69 actor CASTOR (CASZ1) directly interacts with congenital heart disease 5 protein (CHD5), which is also

70 In patients without congenital heart disease, 53% had dilated cardiomyopathy

71 The number of patients with adult congenital heart disease (ACHD) is rapidly increasing.

72 Adult congenital heart disease (ACHD) patients have ongoing mo

73 (SCD) is a major cause of mortality in adult congenital heart disease (ACHD) patients.

74 mmon end-stage syndrome for many adults with congenital heart disease (ACHD).

75 cterizing disease activity among adults with congenital heart disease (ACHD).

76 Congenital heart disease affects more than 1% of livebor

77 e study of 29 638 Quebec patients with adult congenital heart disease aged 18 to 64 years between 199

78 with 22q11.2DS, a total of 62% (n=906) have congenital heart disease and 36% (n=326) of these have t

79 2013, there were 2734 deaths due to critical congenital heart disease and 3967 deaths due to other/un

80 cardiac medicine, including the diagnosis of congenital heart disease and arrhythmias, assessment of

81 nter cohort study enrolled 482 patients with congenital heart disease and atrial arrhythmias, age 32.

82 whole exome studies in neonatal arrhythmia, congenital heart disease and coronary artery disease tha

83 Among the birth defects, congenital heart disease and craniofacial malformations

84 h leakage as a cause of PLE in patients with congenital heart disease and elevated central venous pre

85 that may contribute to our understanding of congenital heart disease and have implications for the d

86 In a patient with congenital heart disease and heterotaxy, a disorder of l

87 in many patients with repaired or palliated congenital heart disease and in those with pulmonary hyp

88 tate newborn screening policies for critical congenital heart disease and infant death rates.

89 ur understanding of the potential origins of congenital heart disease and inform future strategies in

90 ysmaturation is also evident in infants with congenital heart disease and is detectable prior to surg

91 ence concerns both families of children with congenital heart disease and medical providers.

92 hrough next-generation sequencing focused on congenital heart disease and neurodevelopmental disorder

93 myocardial wall can lead to various forms of congenital heart disease and non-compaction cardiomyopat

94 ies of 18 patients with surgically corrected congenital heart disease and plastic bronchitis who pres

95 d a retrospective review of 25 patients with congenital heart disease and post-operative chylothorax

96 y, and manifestations of HF in children with congenital heart disease and presents the clinical, gene

97 In patients with congenital heart disease and right bundle branch block,

98 the knowledge on epidemiology of adults with congenital heart disease and their complications during

99 y hypertension is frequently associated with congenital heart disease and various infectious disorder

100 hildren, including 60% <1 year old, 60% with congenital heart disease, and 54% after cardiac surgery.

101 ge was 10.1+/-6.4 years, 47% of patients had congenital heart disease, and 80% of these patients had

102 associated with inherited cardiomyopathies, congenital heart disease, and cardiac development.

103 e newborn care, pulse oximetry screening for congenital heart disease, and circumcision.

104 of whole-exome sequence data in epilepsy and congenital heart disease, and demonstrate EvoTol's abili

105 patients with Eisenmenger syndrome, complex congenital heart disease, and Fontan physiology had much

106 ng of Notch function in cardiac development, congenital heart disease, and heart regeneration.

107 malities, congenital malformations including congenital heart disease, and musculoskeletal features.

108 e unique stressors on the RV associated with congenital heart disease, and the need to better underst

109 onsiderations for data integration models in congenital heart disease, and the short- and long-term v

110 of infant EFE development in heterogeneous, congenital heart diseases, and to bone morphogenetic pro

111 Infants with complex congenital heart disease are at high risk for poor neuro

112 Children with congenital heart disease are at risk for developmental d

113 ut clinical performance data for adults with congenital heart disease are limited.

114 patients with restrictive heart disease and congenital heart disease are more likely to die while aw

115 e-threonine kinase family, in a patient with congenital heart disease associated with abnormal LR dev

116 Specific physiology explains some congenital heart disease at altitude.

117 of elective delivery of fetuses with complex congenital heart disease at early term.

118 Children with congenital heart disease at high risk for developmental

119 endation that routine screening for cyanotic congenital heart disease be added to the panel of univer

120 The impact of maternal age on congenital heart disease can be modelled in mouse pups t

121 Studies have shown that patients with congenital heart disease can improve physical exercise c

122 Next we evaluate known human congenital heart diseases: cardiomyopathy and heterotaxy

123 For many women with complex congenital heart disease, carrying a pregnancy carries a

124 Critical congenital heart disease (CCHD) was added to the Recomme

125 ostering a competitive environment for adult congenital heart disease centers or at least avoiding cr

126 Congenital heart disease (CHD) affects up to 1% of live

127 Pre-natal diagnosis of congenital heart disease (CHD) allows anticipation of ur

128 creen and show that 29% of mutations causing congenital heart disease (CHD) also cause renal anomalie

129 2q11DS), of whom 89 case subjects had severe congenital heart disease (CHD) and 95 control subjects h

130 and for improvement in prenatal diagnosis of congenital heart disease (CHD) and arrhythmias.

131 ioventricular nodal reentrant tachycardia to congenital heart disease (CHD) and the outcome of cathet

132 Patients with congenital heart disease (CHD) are assumed to be vulnera

133 as become evident that individuals born with congenital heart disease (CHD) are at risk of developing

134 Adults with congenital heart disease (CHD) are exposed to increasing

135 Congenital heart disease (CHD) constitutes the most prev

136 atherosclerotic structural heart disease and congenital heart disease (CHD) data collection.

137 Congenital heart disease (CHD) has a multifactorial path

138 Structural congenital heart disease (CHD) has not previously been l

139 The number of patients surviving with congenital heart disease (CHD) has soared over the last

140 ancy and quality of life for those born with congenital heart disease (CHD) have greatly improved ove

141 GWAS) identified two susceptibility loci for congenital heart disease (CHD) in Han Chinese.

142 tween maternal diabetes mellitus and risk of congenital heart disease (CHD) in offspring.

143 Congenital heart disease (CHD) is a leading cause of mor

144 Congenital heart disease (CHD) is an enigma.

145 Our understanding of the genetics of congenital heart disease (CHD) is rapidly expanding; how

146 Congenital heart disease (CHD) is the leading cause of m

147 Congenital heart disease (CHD) is the most common birth

148 Congenital heart disease (CHD) is the most common type o

149 Congenital heart disease (CHD) is the most prevalent bir

150 om medical procedures among individuals with congenital heart disease (CHD) is unknown.

151 Women with congenital heart disease (CHD) may be at increased risk

152 Congenital heart disease (CHD) patients have an increase

153 reen candidate disease genes identified from Congenital Heart Disease (CHD) patients.

154 Congenital heart disease (CHD) remains a leading cause o

155 Congenital heart disease (CHD) represents the most preva

156 ement, there are now more adults living with congenital heart disease (CHD) than children.

157 ial septal defects (ASDs) are a common human congenital heart disease (CHD) that can be induced by ge

158 lationship of prenatal diagnosis of critical congenital heart disease (CHD) with brain injury and bra

159 Congenital heart disease (CHD), a prevalent birth defect

160 the diagnosis and treatment of children with congenital heart disease (CHD), allowing for longer life

161 cardiac transcription factor gene TBX5 cause congenital heart disease (CHD), although the underlying

162 genomics is identifying candidate genes for congenital heart disease (CHD), but discovering the unde

163 t common comorbidity associated with complex congenital heart disease (CHD), while the underlying bio

164 defects (AVSDs) are a common severe form of congenital heart disease (CHD).

165 iomyopathy is a common cause of mortality in congenital heart disease (CHD).

166 f regionalized systems of care for pediatric congenital heart disease (CHD).

167 for atrial tachyarrhythmias in patients with congenital heart disease (CHD).

168 s have been implicated in the development of congenital heart disease (CHD).

169 letions observed in humans and is related to congenital heart disease (CHD).

170 gnificant source of morbidity in adults with congenital heart disease (CHD).

171 s a central role in caring for patients with congenital heart disease (CHD).

172 monary arterial hypertension associated with congenital heart disease (CHD-PAH) has serious consequen

173 with an age-matched comparison group without congenital heart disease (CHD; P=0.0004).

174 ecember 2014 identified 52,200 patients with congenital heart diseases (CHD) referred for CCTA, echoc

175 by pre-HTx diagnosis into cardiomyopathy and congenital heart disease cohorts.

176 children with DS have a higher incidence of congenital heart disease compared with their peers.

177 on of arrhythmias due to IART increased with congenital heart disease complexity from 47.2% to 62.1%

178 main to ensure that children and adults with congenital heart disease continue to benefit from an exp

179 nificant dysregulation following surgery for congenital heart disease, contributing to organ failure

180 Part One includes the sections: Congenital Heart Disease, Coronary Disease & Interventio

181 Part One includes the sections: Congenital Heart Disease, Coronary Disease & Interventio

182 yopathies/Myocardial & Pericardial Diseases, Congenital Heart Disease, Coronary Disease & Interventio

183 Part One includes the sections: Congenital Heart Disease, Coronary Disease & Interventio

184 Part One includes the sections: Congenital Heart Disease, Coronary Disease & Interventio

185 yopathies/Myocardial & Pericardial Diseases, Congenital Heart Disease, Coronary Disease & Interventio

186 y an interest in understanding the causes of congenital heart disease coupled with the potential of u

187 s report summarizes the current landscape of congenital heart disease data, data integration methodol

188 1990 and 2005 in the population-based Quebec Congenital Heart Disease database (n=71 467).

189 The study population derived from the Quebec Congenital Heart Disease Database.

190 Critical congenital heart disease death rates in states with mand

191 cessful outcome in the care of patients with congenital heart disease depends on a comprehensive mult

192 case of left ventricular non-compaction with congenital heart disease, disturbance of the NOTCH signa

193 Maternal age is a risk factor for congenital heart disease even in the absence of any chro

194 However, implementation of dedicated congenital heart disease follow-up programs presents imp

195 present a common but heterogeneous subset of congenital heart disease for which gene identification h

196 iac transcription factor MEF2C and the human congenital heart disease gene TDGF1.

197 additional probes as more cardiomyopathy and congenital heart disease genes are discovered, giving re

198 Palliative surgery for congenital heart disease has allowed patients with previ

199 operative care in the pediatric patient with congenital heart disease has become a reduction in lengt

200 ver the past decades, the landscape of adult congenital heart disease has changed dramatically, which

201 products to promote cardiac regeneration in congenital heart disease has demonstrated significant im

202 The success in the management of congenital heart disease has resulted in a growing popul

203 transcription factor that has been linked to congenital heart disease has wider effects than previous

204 Percutaneous therapies for congenital heart disease have evolved rapidly in the pas

205 Patients with adult congenital heart disease have high rates of readmission,

206 Although surgical outcomes for congenital heart disease have improved over the decades,

207 predominantly driven by patients with severe congenital heart disease (hazard ratio, 0.38; 95% CI, 0.

208 e an indispensable tool in the evaluation of congenital heart disease, heart failure, cardiac masses,

209 Defects in either result in severe congenital heart disease; however, little is known about

210 tly not recommended for patients with simple congenital heart disease; however, only a few data exist

211 r than 50% (HR, 0.57; 95% CI, 0.34-0.97) and congenital heart disease (HR, 0.78; 95% CI, 0.64-0.96).

212 esin genes may be causative of a fraction of congenital heart disease in human populations.

213 Mutations in NOTCH signaling elements cause congenital heart disease in humans and mice, demonstrati

214 ns in CCDC11 disrupt L-R asymmetry and cause congenital heart disease in humans, yet the molecular an

215 me 21 in the proposed region responsible for congenital heart disease in individuals with Down's synd

216 Patients diagnosed with simple congenital heart disease in the 1960s have substantially

217 OF), comprising the largest subset of severe congenital heart disease in the cohort.

218 hyltransferase, has been implicated in human congenital heart disease in the context of Kabuki syndro

219 lastic left heart syndrome (HLHS) is a fatal congenital heart disease in which the left side of the h

220 and translational research studies of HF in congenital heart disease including at the genome, transc

221 elivery planning strategies for fetuses with congenital heart disease including models based on class

222 urvival after prenatal diagnosis of critical congenital heart disease, including hypoplastic left hea

223 For patients with congenital heart disease, independent risk factors were

224 lant recipients with PRA greater than 50% or congenital heart disease, induction therapy is associate

225 mutations in this domain that are linked to congenital heart disease interfere with CycD2-GATA4 syne

226 a new group of patients, those who survived congenital heart disease into adulthood, emerged.

227 About two-thirds of human congenital heart disease involves second heart field-der

228 Post-operative chylothorax in patients with congenital heart disease is a challenging problem with s

229 age of branching arteries without coexisting congenital heart disease is a very rare anomaly.

230 esis, it is not surprising that some form of congenital heart disease is present in approximately 1 p

231 Although congenital heart disease is reported in families with mu

232 Pulse oximetry screening for cyanotic congenital heart disease is specific, sensitive and meet

233 Congenital heart disease is the leading cause of death i

234 Congenital heart disease is the most common birth defect

235 Congenital heart disease is the most frequently occurrin

236 ave better or worse outcomes after repair of congenital heart disease is unclear.

237 hase of heart development, during which many congenital heart disease malformations likely arise, we

238 whether advances in the management of adult congenital heart disease may reduce this substantial str

239 We take a functional genomics approach to congenital heart disease mechanism.

240 monary hypertension associated with repaired congenital heart disease (n=17) or lung disease (n=3).

241 hereditary PAH (n=25) or PAH associated with congenital heart disease (n=18) were enrolled in a prosp

242 in patients with cardiomyopathy (n=896) and congenital heart disease (n=965).

243 selective causes of infant death, pneumonia, congenital heart disease, neural tube defects, preterm b

244 terogeneity of interventional procedures for congenital heart disease, new procedure-type risk catego

245 is a highly accurate diagnostic modality for congenital heart diseases, obviating the need for invasi

246 ar mixed effects model, presence of cyanotic congenital heart disease (odds ratio, 7.35; p < 0.001) a

247 ct (RVOT) dysfunction, patients with complex congenital heart disease of the RVOT traditionally requi

248 owth, and which is typically associated with congenital heart diseases of heterogeneous origin, such

249 Congenital heart disease often features structural abnor

250 nts with left ventricular non-compaction and congenital heart disease often need surgical or catheter

251 patients 10 to 35 years of age undergoing a congenital heart disease operation in the Society of Tho

252 Thus, among patients with previous congenital heart disease or cardiomyopathy, disease-spec

253 ours and 6 months of age) coded for critical congenital heart disease or other/unspecified congenital

254 cardiac arrhythmia, cerebrovascular disease, congenital heart disease, or admissions with cardiac sym

255 ongenital malformation, with subanalyses for congenital heart disease, oral cleft, and limb deficienc

256 (IPAH/FPAH) and 105 had PAH associated with congenital heart disease (PAH-CHD).

257 ilencing of Tgf-beta1, a causative factor in congenital heart disease pathogenesis, in a deacetylase-

258 native to surgical valve replacement for the congenital heart disease patient with right ventricular

259 e effect of BMI on perioperative outcomes in congenital heart disease patients has not been evaluated

260 e useful for the diagnosis and management of congenital heart disease patients with pulmonary overcir

261 ree populations: childhood cancer survivors, congenital heart disease patients, and those with intell

262 e follow-up study of a cohort of 1241 simple congenital heart disease patients, diagnosed from 1963 t

263 ICD implantation is feasible for adults with congenital heart disease patients.

264 In the care of patients with congenital heart disease, percutaneous interventional tr

265 ations, and heart failure in the adults with congenital heart disease population.

266 cutive patients from the pediatric and adult congenital heart disease programs were enrolled.

267 and 60% to 70% of affected individuals have congenital heart disease, ranging from mild to severe.

268 ly due to the increased number of women with congenital heart disease reaching childbearing age and t

269 in 9 (36%) of pediatric and 1 (9%) of adult congenital heart disease-repaired patients.

270 s >/=48 hours, admission >/=14 days of life, congenital heart disease requiring surgical repair at <7

271 es related to an integrated data network for congenital heart disease research.

272 Although concentrating adult congenital heart disease services at high-volume centers

273 TPN11 gene encoding Shp2, which manifests in congenital heart disease, short stature, and facial dysm

274 autosomal dominant disorder characterized by congenital heart disease, skeletal abnormalities, and fa

275 have transformed the clinical management of congenital heart disease, such as hypoplastic left heart

276 women, however, do not have access to adult congenital heart disease tertiary centers with experienc

277 LV dilation and dysfunction, hypertrophy, or congenital heart disease, the genetic cause may overlap.

278 s encountered when caring for the adult with congenital heart disease through a review of recently pu

279 Early infant deaths from critical congenital heart disease through December 31, 2013, decr

280 ic-health guidelines recommend patients with congenital heart disease to exercise.

281 ry referral centers with a specialized adult congenital heart disease unit.

282 patient choice and competition between adult congenital heart disease units and to investigate whethe

283 Competition between the 10 major adult congenital heart disease units in England was evaluated

284 7.2) and 65.2 kg (17.7-107); 14 patients had congenital heart disease (univentricular heart with a ri

285 In 2011, critical congenital heart disease was added to the US Recommended

286 policies for newborn screening for critical congenital heart disease was associated with a significa

287 ears who underwent surgical intervention for congenital heart disease were identified using the Kids'

288 A total of 1593 surgical procedures for congenital heart disease were performed.

289 patients (21 male; mean age: 8.5 month) with congenital heart diseases were reviewed and the paramete

290 ve surgery could transform the management of congenital heart disease when cost-effective strategies

291 XD flow, is demonstrated for (a) evaluating congenital heart disease, where the impact of bulk motio

292 ents (49+/-13 years; 74% male) with repaired congenital heart disease who underwent radiofrequency ca

293 Patients with complex congenital heart disease, who may have undergone previou

294 Today, most female children born with congenital heart disease will reach childbearing age.

295 tients with liver lymphatic embolization and congenital heart disease with elevated central venous pr

296 In patients with repaired congenital heart disease with preserved ventricular func

297 atheter approach for an adult with untreated congenital heart disease with severe cyanosis and signif

298 resenting atrial arrhythmia in patients with congenital heart disease, with a predominantly paroxysma

299 is most commonly attributable to coexistent congenital heart disease, with different risks depending

300 Patients with congenital heart disease, with endocarditis, and undergo